Public Offerings, Merger Agreements, New Preclinical Data, New Treatments and Dividend Payments - Research Report on XOMA, MAKO, Alnylam, Avanir, and PDL BioPharma PR Newswire NEW YORK, December 18, 2013 NEW YORK, December 18, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting XOMA Corporation (NASDAQ: XOMA), MAKO Surgical Corp. (NASDAQ: MAKO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Avanir Pharmaceuticals (NASDAQ: AVNR), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. XOMA Corporation Research Report On December 13, 2013, XOMA Corp. (XOMA) announced the pricing of 9.5 million shares of its common stock at a price to the public of $5.25 per share. The Company reported that it has also granted the underwriters a 30-day option to purchase up to an additional approximately 1.4 million shares of common stock on the same terms and conditions. XOMA informed that after deducting the underwriting discount and estimated offering expenses payable by the Company, the aggregate net proceeds from the offering will amount to approximately $46.5 million, which the Company intends to use for continued development, preclinical testing and clinical studies related to gevokizumab and the XMet platform, general research and development, business development and other corporate purposes. The Company expects the offering to close on or about December 18, 2013. The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9a56_XOMA MAKO Surgical Corp. Research Report On December 13, 2013, MAKO Surgical Corp. (MAKO) announced the Mako stockholders' approval of the adoption of the Agreement and Plan of Merger in relation to the merger of MAKO with and into a wholly owned subsidiary of Stryker Corporation. Under the terms of the Merger Agreement, MAKO stockholders will receive $30 per share in cash at the closing of the merger. The parties expect the transaction to close on December 17, 2013. The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7465_MAKO Alnylam Pharmaceuticals, Inc. Research Report On December 9, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the presentation of new pre-clinical data with ALN-AT3 at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - December 10, 2013 in New Orleans. Alnylam reported that ALN-AT3 is a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD). The studies demonstrated that the repeat administration of ALN-AT3 was found to be well tolerated in Hemophilia A (HA) mice, with no adverse findings up to dose levels 200 times greater than levels required to achieve 50% AT knockdown. According to the Company, the ALN-AT3 administration also demonstrated complete correction of the activated Partial Thromboplastin Time (aPTT) - an ex vivo measure of blood coagulation that is significantly prolonged in hemophilia - in HA mice. Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, commented, "These new data presented at ASH demonstrate that repeat administration of ALN-AT3 is well tolerated in animal models of hemophilia, and suggest that our RNAi therapeutic has the potential for a wide therapeutic index in subjects with hemophilia. With MHRA approval of our recently filed CTA, we look forward to the advancement of ALN-AT3 in our Phase I clinical trial that we expect to start in early 2014, with data from hemophilia subjects expected by the end of next year." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5b29_ALNY Avanir Pharmaceuticals Research Report On December 10, 2013, Avanir Pharmaceuticals (Avanir) reported its Q4 FY 2013 financial results (period ended September 30, 2013). The Company reported total net revenues of $21.7 million, compared with $13.5 million in Q4 FY 2012. Net loss totaled $15.4 million or $0.10 per diluted share, compared with a net loss of $11.7 million or $0.09 per diluted share in Q4 FY 2012. For fiscal 2013, total net revenues were $75.4 million, 82.6% YoY growth. Net loss for full-year 2013, was $55.5 million or $0.39 per diluted share, compared with a net loss of $59.7 million or $0.45 per diluted share in full-year 2012. Keith A. Katkin, President and CEO of Avanir commented, "We have achieved a number of important and transformational milestones. In addition to robust growth of NUEDEXTA for PBA, we formed a co-promote partnership with Merck which will leverage our commercial leadership in the institutional setting. We also in-licensed a new investigational migraine treatment, gained European approval for NUEDEXTA and initiated a new phase II study of AVP-923 exploring its potential application in levadopa-induced dyskinesias in Parkinson's disease." The Full Research Report on Avanir Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2ee8_AVNR PDL BioPharma, Inc. Research Report On December 12, 2013, PDL BioPharma, Inc. (PDL BioPharma) announced the completion of its regular quarterly dividend payment. The Company has successfully paid the December 12, 2013 dividend payment of $0.15 per share to all stockholders owning shares as of December 5, 2013, the record date. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/066b_PDLI EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Public Offerings, Merger Agreements, New Preclinical Data, New Treatments and Dividend Payments - Research Report on XOMA, MAKO,
Press spacebar to pause and continue. Press esc to stop.